48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006402:Hematologic Diseases / Q000188:drug therapy; D006405:Hematology; D006801:Humans; D000077269:Lenalidomide; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy*; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D015363:Quinolones / Q000008:administration & dosage; D012008:Recurrence; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
D001897:Boronic Acids; D011719:Pyrazines; D015363:Quinolones; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide; C402769:tipifarnib; D008558:Melphalan; D011241:Prednisone